Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
Mol Neurobiol. 2018 Dec;55(12):8885-8903. doi: 10.1007/s12035-018-1016-x. Epub 2018 Apr 2.
Here, we review a novel concept namely the compensatory immune-regulatory reflex system (CIRS) as applied to the pathophysiology of major depressive disorder (MDD) and bipolar disorder (BD). There is evidence that a substantial subset of individuals with MDD and BD exhibit an activation of the immune-inflammatory response system (IRS), as indicated by an increased production of macrophagic M1 and T helper (Th)-1 pro-inflammatory cytokines, interleukin (IL)-6 trans-signaling, positive acute phase proteins (APPs), and complement factors. These immune aberrations appear to be evident during the course of major affective episodes of either depressive or (hypo) manic polarity. Here, we review (a) the current state of the art of CIRS functions in both mood disorders and (b) the possible role of CIRS-related biomarkers for the understanding of affective disorders within the framework of precision psychiatry that could also provide novel drug targets for both MDD and BD. CIRS-related abnormalities in mood disorders include elevated Th-2 and T regulatory (Treg) activities with increased IL-4 and IL-10 production, classical IL-6 signaling, increased levels of sIL-1R antagonist (sIL-1RA), soluble IL-2 (sIL-2R) and tumor necrosis factor-α- receptors, and positive APPs, including haptoglobin, hemopexin, α1-acid glycoprotein, α1-antitrypsin, and ceruloplasmin. It is concluded that CIRS is involved in MDD and BD by regulating the primary immune-inflammatory response, thereby contributing to spontaneous and antidepressant-promoted recovery from the acute phase of illness. Signs of activated IRS and CIRS pathways are observed in the remitted phases of both disorders indicating that there is no return to the original homeostasis after an acute episode, while later episodes of mood disorders are characterized by sensitized IRS and CIRS responses. New z-unit weighted composite biomarker scores are proposed, which reflect different aspects of IRS versus CIRS activation and may be used to estimate different IRS/CIRS activity ratios in mood and other neuroimmune disorders.
在这里,我们回顾了一个新的概念,即代偿性免疫调节反射系统(CIRS),该系统应用于重性抑郁障碍(MDD)和双相情感障碍(BD)的病理生理学。有证据表明,相当一部分 MDD 和 BD 患者表现出免疫炎症反应系统(IRS)的激活,表现为巨噬细胞 M1 和辅助性 T 细胞(Th)-1 促炎细胞因子、白细胞介素(IL)-6 转导信号、急性期蛋白(APPs)和补体因子的产生增加。这些免疫异常似乎在抑郁或(低)躁狂极性的主要情感发作过程中明显。在这里,我们回顾了(a)CIRS 在心境障碍中的作用的最新进展,以及(b)CIRS 相关生物标志物在精准精神病学框架下理解情感障碍的可能作用,这也为 MDD 和 BD 提供了新的药物靶点。心境障碍中的 CIRS 相关异常包括升高的 Th-2 和 T 调节(Treg)活性,伴有增加的 IL-4 和 IL-10 产生、经典的 IL-6 信号传导、增加的可溶性 IL-1R 拮抗剂(sIL-1RA)、可溶性 IL-2(sIL-2R)和肿瘤坏死因子-α-受体以及急性期蛋白,包括触珠蛋白、血红素结合蛋白、α1-酸性糖蛋白、α1-抗胰蛋白酶和铜蓝蛋白。结论是,CIRS 通过调节初级免疫炎症反应参与 MDD 和 BD,从而有助于从疾病的急性期自发和抗抑郁治疗中恢复。在两种疾病的缓解期都观察到 IRS 和 CIRS 途径的激活迹象,这表明在急性发作后不会恢复到原来的平衡状态,而后来的心境障碍发作则以 IRS 和 CIRS 反应的敏感化为特征。提出了新的 z 单位加权综合生物标志物评分,它反映了 IRS 与 CIRS 激活的不同方面,可用于估计心境和其他神经免疫障碍中不同的 IRS/CIRS 活性比。